**K\textsubscript{ca}3.1 Activation Via P2Y\textsubscript{2} Purinergic Receptors Promotes Human Ovarian Cancer Cell (Skov-3) Migration**

L. Robles-Martínez\textsuperscript{1}, E. Garay\textsuperscript{1}, M. G. Martel-Gallegos\textsuperscript{1}, A. Cisneros-Mejorado\textsuperscript{1}, D. Pérez-Montiel\textsuperscript{2}, A. Lara\textsuperscript{1} & R. O. Arellano\textsuperscript{1}\textsuperscript{,}\textsuperscript{3}

Disorders in cell signaling mediated by ATP or histamine, activating specific membrane receptors, have been frequently associated with tumorigenesis. Among the elements of response to purinergic (and histaminergic) signaling, ion channel activation controls essential cellular processes in cancer, such as cell proliferation, motility, and death. Here, we studied the effects that ATP had on electrical properties of human ovarian adenocarcinoma cells named SKOV-3. ATP caused increase in intracellular Ca\textsuperscript{2+} concentration ([Ca\textsuperscript{2+}]\textsubscript{i}) and, concurrently, it evoked a complex electrical response with a conspicuous outward component. This current was generated through P2Y\textsubscript{2} receptor activation and opening of K\textsuperscript{+} channels, K\textsubscript{ca}3.1, as indicated by electrophysiological and pharmacological analysis, as well as by immunodetection and specific silencing of P2Y\textsubscript{2} or K\textsubscript{ca}3.1 gene by esiRNA transfection. Low \(\mu\text{M}\) ATP concentration increased SKOV-3 cell migration, which was strongly inhibited by K\textsubscript{ca}3.1 channel blockers and by esiRNA-generated P2Y\textsubscript{2} or K\textsubscript{ca}3.1 downregulation. Finally, in human ovarian tumors, the P2Y\textsubscript{2} and K\textsubscript{ca}3.1 proteins are expressed and co-localized in neoplastic cells. Thus, stimulation of P2Y\textsubscript{2} receptors expressed in SKOV-3 cells promotes motility through K\textsubscript{ca}3.1 activation. Since P2Y\textsubscript{2} and K\textsubscript{ca}3.1 are co-expressed in primary tumors, our findings suggest that they may play a role in cancer progression.

Evidence supports a relationship between alterations in the purinergic or histaminergic signaling systems and the cancer process in several cell types\textsuperscript{1,2}. Thus, stimulation of specific, ATP-sensitive membrane receptors, named P2 receptors, inhibits cell growth and/or promotes apoptosis in various cancer cells such as breast cancer\textsuperscript{3}, cervical cancer\textsuperscript{4}, glioma\textsuperscript{5}, and prostate cancer\textsuperscript{6}, among many others. However, purinergic stimulation might also have the opposite effect as it can promote cell proliferation, either in distinct cancer cell types or even in the same model when tested in different experimental conditions. These divergent effects have been thought to reflect ATP availability in the tumor environment together with a specific combination of purinergic membrane receptors expressed in a particular cell type\textsuperscript{7}, and in addition, they would be strongly influenced by the expression of a distinctive set of effector proteins, such as G proteins, protein kinases, and membrane ion channels. Histaminergic signaling that is altered in cancer has also been proposed as an important paracrine and autocrine regulator of proliferation\textsuperscript{8}, as well as a mediator of cancer progression acting on cell migration, angiogenesis, and modulation of the immune response.

Previous studies indicated that ion channel function might be one of the modifications suffered in cancer; their activation or inhibition, for example, affects various important functional processes in the context of cancer\textsuperscript{9,10}. Altered expression of a diversity of K\textsuperscript{+} channels in human breast cancer cells, in human astrocytomas and glioblastomas, and in human ovarian cells including SKOV-3 have been documented in distinct cell models\textsuperscript{11,12}. Although ion channel activation through purinergic receptor stimulation is a well-known phenomenon, its role in cancer has not been thoroughly analyzed. Here, we undertake an analysis of the effects mediated by ATP (and

---

\textsuperscript{1}Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Juriquilla Querétaro, CP 76230, Querétaro, México, Mexico. \textsuperscript{2}Departamento de Patología, Instituto Nacional de Cancerología, Secretaría de Salud, Av. San Fernando #22, Colonia Sección XVI, Tlalpan, CP 14080, Ciudad de México, México, Mexico. Correspondence and requests for materials should be addressed to R.O.A. (email: arellano.ostoa@comunidad.unam.mx)
**Results**

**ATP triggers complex electrical membrane responses in SKOV-3 cells.** Electrophysiological experiments were made in SKOV-3 cells between passages 1 to 6, within a period of 48–72 h in culture. Single cells, or those with no more than 1 or 2 in contact, were chosen in order to avoid extensive cell coupling, although it has been shown previously that SKOV-3 cells have a low level of cell-to-cell coupling mediated through gap junction channels under similar culture conditions\(^1\). Thus, SKOV-3 cells presented a \(C_m\) of 48.9 ± 1.5 pF and \(R_m\) of 127.5 ± 17.8 MΩ (359 cells) as monitored in whole cell configuration using the standard internal and external solutions. SKOV-3 cells held at −40 mV a value close to their resting membrane potential (−38.8 ± 2.4 mV) were systemically tested for different agonists. ATP (1–100 \(\mu\)M) application elicited in 92.3 ± 3% of the cells a complex electrical response consistently composed of 3 main components (denoted components 1–3 in Fig. 1A), which was associated with an increase in membrane conductance: a fast, inward response of low amplitude (1) followed by a robust outward current (2) that developed together with a smaller, slower, and relatively less frequent inward current (3). Component 2 was the main membrane current elicited by ATP, and it had an average amplitude of 26.24 ± 2.5 pA/pF (n = 186 cells). Typically, the current response to ATP decreased after 2 to 3 applications with washing intervals of 3–4 min, and the response disappeared completely after 5 to 8 sequential applications (data not shown).

Other agonists were tested for their ability to activate membrane currents (Fig. 1B). Among them, UTP (n = 33) or histamine (n = 9) also generated current responses that mimicked mainly component 2 (12.91 ± 2.1 pA/pF and 7.3 ± 1.05 pA/pF for UTP and histamine, respectively). It appears that current component 1 is specific for ATP. All other agonists, such as acetylcholine, adenosine or dopamine (Fig. 1B), failed to activate any response (4 cells in each case). Thus, these data strongly suggest that current responses were specific for purinergic and histaminergic receptors. We also explored the ATP sensitivity of the ovarian adenocarcinoma cell line named CaOV-3 (n = 10), where 10 \(\mu\)M ATP application generated similar current components 1 and 2, with an average amplitude of 0.47 ± 0.007 pA/pF and 17.4 ± 3.8 pA/pF, respectively.
A human P2Y4 receptor is not activated by ATP 22. All these data strongly suggested a main role of P2Y2 in ATP-generated current activated had a reversal potential (E_{rev}) of −95 mV. Similar voltage dependency was also observed in experiments where cells were held at different potentials and then tested by applying 3 µM ATP or UTP generated a robust [Ca^{2+}]_{i} increase that was mimicked by 10 µM histamine, as previously shown 16.

As illustrated in Fig. 2B, it was also demonstrated that the electrical response generated by ATP application was dose dependent; in these experiments, cells held at -40 mV were perfused with increasing concentrations of ATP within the range of 0.1 to 30 µM with wash intervals of 4–5 min. The peak response at each concentration was normalized against the maximal current that occurred around 3 µM. The dose-response curve gave an estimated EC_{50} of 399 ± 11.4 nM for component 2 elicited by ATP.

Outward membrane response to ATP was mimicked by purinergic agonists. In order to distinguish among different P2 receptors, a battery of agonists was tested, all at 3 µM concentration (Fig. 3A). In Fig. 3B bars illustrate the current response elicited by the different drugs, normalized against that obtained by ATP application in the same cell. This gave the following sequence of potency: ATP > UTP-S > UTP > ATP-S > Ap4A ≥ 2-MeSATP ≥ Bz-ATP ≥ 5 Br-UDP ≥ ADP ≥ 2-MeSADP ≫ UDP; with no response to adenosine. All agonists tested generated mainly the outward current, although the more potent drugs, such as UTP, also elicited component 3 in a way similar to ATP, but not component 1. This strongly suggested that the receptor involved in generating the outward current was one of the P2Y subtypes sensitive to UTP with a pharmacological profile close to that displayed for the P2Y2 subtype.

Three different P2Y-type receptors sensitive to UTP are known in different species 20, 21; these are named the P2Y2, P2Y4 and P2Y6 receptors. Thus, an RT-PCR analysis was made to specifically amplify the transcripts for P2Y2, P2Y4 and P2Y6 receptors. This gave the following sequence of expression: P2Y2, P2Y4 and P2Y6 were also well expressed in 90% of cells tested (Fig. 3C). Immunocytochemistry against these receptors in SKOV-3 cells indicated that P2Y2 and P2Y4 proteins were also well expressed in 90% of cells tested (Fig. 3C). However, it is well known that the human P2Y1 receptor is not activated by ATP 22. All these data strongly suggested a main role of P2Y2 in ATP- or UTP-elicited outward current response of SKOV-3 cells. This was also supported by the inhibitory effect of AR-C118925 (10–30 µM), an antagonist with high specificity for P2Y2 receptors 23, that reduced 80–88% of the response elicited by ATP (3 µM) and more than 98% of the response to UTP (3 µM) (Fig. 3D,E); while NF340 or MR52179, specific antagonists for P2Y1 and P2Y1 subtypes 24, respectively, did not affect SKOV-3 responses generated by ATP.

Ionic basis for the outward current generated by ATP. Current-voltage (I/V) relationships were built by applying voltage steps in control conditions and at the peak of the outward current activated by ATP; the differences between these two relations were plotted as illustrated in Fig. 4A. The I/V curve showed that the outward current activated had a reversal potential (E_{rev}) of −95 ± 5 mV (n = 54), which corresponded closely to that for K^+ ions in the recording conditions. Similar voltage dependency was also observed in experiments where cells were held at different potentials and then tested by applying 3 µM ATP. As shown in Fig. 4B, component 2 of the response inverted polarity close to −100 mV. Using the voltage-stepping protocol and increasing the concentration of K^+ (substituted for Na^+) in the external solution, the current E_{rev} shifted to less negative values; thus in 60 mM K^+ it was −20 ± 9 mV, and in 30 mM K^+ the E_{rev} was −35 ± 5 mV. As shown in Fig. 4C the logarithmic
relation of $E_{rev}$ versus extracellular $K^+$ concentration was a line with a slope of $-59$ mV, in agreement with the Nernst equation. Also, I/V curves were built during the development of component 3 after the complete wash out of component 2; in this condition inward currents had an $E_{rev}$ of $-2\pm1$ mV ($n=10$) and were not affected by T16Ainh-A01 (100 µM; $n=5$), a specific Ca$^{2+}$-dependent Cl$^-$ channel blocker.

**Effect of $K^+$ channel blockers and expression of $K_{Ca3.1}$ channels.** Consistent with a conducting pathway for $K^+$ ions during component 2, the ATP response was inhibited by 5 mM tetraethylammonium (TEA+) or 5 mM 4-aminopyridine (4-AP), unselective $K^+$ channel blockers (18 cells for each blocker), by $67\pm7\%$ and $70\pm4\%$, respectively (Fig. 5B). Similar results were obtained for outward currents activated by UTP. Together, these results indicated that purinergic activation opened a conductance selective for $K^+$ ions; thus, we tested various drugs that act selectively on $K^+$ channels that have been shown to either be expressed in SKOV-3 cells or be involved in tumor biology (Fig. 4D–H). Specific blockers of two-pore $K^+$ channels known to be overexpressed in SKOV-3 cells, such as 20 µM curcumin, 100 µM L-methionine, 100 µM TPenA (a TREK-1 and TREK-2 blocker), and 20 µM methanandamide (a TASK-3 blocker), showed only small inhibitory effects (ranging from 12 to 26%) on the $K^+$ current elicited by ATP (or UTP; $n=22$) that were not significant when compared with the amplitude of control currents. However, application of 10 µM TRAM-34, a specific blocker for intermediate-conductance Ca$^{2+}$-dependent $K^+$ channels ($K_{Ca3.1}$), produced a strong inhibition of $83\pm9\%$ ($n=12$) of the current response elicited by ATP or UTP (Fig. 4D,E), while 1 µM apamin, a potent blocker of the small-conductance Ca$^{2+}$-dependent $K^+$ channel ($K_{Ca2}$) subtype, had a smaller inhibitory effect of $26\pm10\%$ ($n=12$) that was not significant (Fig. 4D). Accordingly, the drug 1-EBIO (100–300 µM), a specific opener for $K_{Ca3.1}$ channels, produced the generation of outward currents in SKOV-3 cells in a manner that was dependent on drug concentration as well as on the free Ca$^{2+}$ concentration in the internal solution (Fig. 4F–H). Also, it was noted that in cells where initial application of 300 µM 1-EBIO was not able to generate a response (6 out of...
18 cells), pre-stimulation with a low dose of 0.5 µM ATP (256.6 ± 61 pA) primed the cells to respond to a second application of 1-EBIO (396 ± 66.7 pA; Fig. 4H). These results indicated that purinergic stimulation of P2Y receptors elicited the activation of K\(^{+}\) channels sensitive to TRAM-34 and 1-EBIO, which are specific drugs for K\(^{+}\)Ca3.1 channels.

A Western blotting was performed to confirm K\(^{+}\)Ca3.1 protein expression in SKOV-3 cells. The results are illustrated in Supplementary Figure S1A where it is shown that an antibody specific against this channel subtype gave a band with the expected weight of 55 KDa for the K\(^{+}\)Ca3.1 channel protein. Immunocytochemical analysis of SKOV-3 cells also showed strong, specific label in most cells in the culture; a positive control using neurons from cortex\(^2\) is shown in Supplementary Figure S1B (see also Fig. 6A and Supplementary Figure S2).

P2Y\(_2\) and K\(^{+}\)Ca3.1 gene silencing by specific esiRNA transfection. Functional and pharmacological results suggested that the purinergic receptor and the ion channel involved in K\(^{+}\) current response were P2Y\(_2\) and K\(^{+}\)Ca3.1, respectively. Thus, knockdown of either P2Y\(_2\) or K\(^{+}\)Ca3.1 protein was made silencing the respective gene, transfecting SKOV-3 cells with specific esiRNA (Fig. 5); then effects of silencing were tested monitoring the electrical response or [Ca\(^{2+}\)]\(_{i}\) change elicited by agonists. Responses were compared with those of cells transfected in parallel with esiRNA of enhanced green fluorescent protein as control (CNT) group. First, esiRNA-transfected SKOV-3 cells were analyzed (24–72 h after transfection) by immunocytochemistry to detect specific expression of P2Y\(_2\) or K\(^{+}\)Ca3.1 protein. Images in Fig. 5A and B illustrate the results; in both cases either P2Y\(_2\)-esiRNA or K\(^{+}\)Ca3.1-esiRNA transfected cells showed a strong signal decrease for the respective protein. SKOV-3 cells transfected with P2Y\(_2\)-esiRNA maintained basal expression of K\(^{+}\)Ca3.1 channel protein, while K\(^{+}\)Ca3.1-esiRNA transfected
cells kept P2Y2 receptor expression (Supplementary Figure S2). esiRNA-transfected SKOV-3 cells, including the control group, were electrophysiologically monitored for responses elicited by ATP or UTP, the more potent agonists; ADP, the weak agonist; and 1-EBIO, the K+ channel positive modulator (Fig. 5C). Both groups of esiRNA-transfected cells showed a strong decrease in electrical response elicited by drug application. A pool of 85 cells from 2–3 different transfections (24–72 h) (Fig. 5D,E) showed that current responses remained low at least for 72 h. For example, 24 h after P2Y2-esiRNA transfection, ATP response decreased by 90.65 ± 4.7%, UTP by 87.75 ± 6.5%, while ADP and 1-EBIO decreased by 83.15 ± 3.9% and 96 ± 3.1%, respectively. Similar results were obtained in Kc3.1-esiRNA-transfected cells. It was consistently observed that knocking down P2Y2 receptor also produced a strong decrease in 1-EBIO response (16.92 ± 7.4 pA; n = 19). Nevertheless, as that shown in Fig. 4H, after ATP (3 µM) application, a larger response was activated in P2Y2-esiRNA treated cells tested with a second 1-EBIO (300 µM) superfusion, although amplitudes were significantly decreased compared with control responses (96.65 ± 42.4 pA vs. 539.3 ± 75.1 pA; n = 15). This was not observed in Kc3.1-esiRNA transfected cells where a second 1-EBIO application, after ATP, was ineffective (not shown).

SKOV-3 silenced for P2Y2 or Kc3.1 protein were fluorometrically monitored for [Ca2+]i changes elicited by agonists (ATP, UTP, or ADP) (Fig. 6). The bar graph in Fig. 6A shows that when tested for ATP both groups of esiRNA-transfected cells, P2Y2 or Kc3.1, showed a significant reduction of [Ca2+]i, increase compared with CNT cells. In the case of P2Y2-esiRNA, the reduction was of 69.3 ± 2.98% while for Kc3.1-esiRNA it was of 54.3 ± 4%. A similar result was obtained in cells tested with UTP, where [Ca2+]i increase was reduced by 51 ± 4% and 98 ± 1.5%, respectively. Thus, downregulation of Kc3.1 alone in SKOV-3 cells unexpectedly seemed to affect [Ca2+]i increase by both agonists, suggesting an effect of membrane potential and/or Ca2+ influx on the response. In addition, responses elicited by ADP were reduced compared with the control group, although changes were not statistically significant in such cases.

All these results indicated that downregulation of P2Y2 or Kc3.1 eliminated the electrical response to ATP or UTP, and that strongly reduced the [Ca2+]i increase regularly generated by the same agonists.

**Kc3.1 channel blockage and cell migration elicited by ATP.** In several cell types, an important role attributed to Kc3.1 is its involvement in the migration phenomenon for example in microglia, glioblastoma as well as in fibroblasts and melanoma cells. First, we asked whether stimulation by ATP promoted cell migration in the concentration range that generated the current response. The results from the transwell migration assay are illustrated in Fig. 7A, where we quantified the migration of SKOV-3 cells for 16 h in the absence or presence of 0.3 µM, 0.6 µM or 3 µM ATP. We observed that migration of cells increased significantly in a dose-dependent manner in the presence of ATP at 0.3, 0.6 and 3 µM to 151.1 ± 19.8%, 160.7 ± 15.6%, and 181.6 ± 22.4%, respectively. Control experiments showed that ATP in the concentrations used did not affect cell proliferation or survival within the 16-h incubation period (using the MTS assay), in agreement with previous studies.
studies. Migration of SKOV-3 cells was also stimulated by UTP and histamine, suggesting a close correlation of the effects exerted by receptors that generated a [Ca\(^{2+}\)] increase, current generation and migration induction. Thus, we tested whether the K\(^{+}\) current carried through K\(_{Ca3.1}\) channels was also involved in the ATP-mediated migration increase. This is illustrated in Fig. 7C where it is shown that 100 µM 1-EBIO applied alone increased the phenomenon, while K\(^{+}\) channel blockers applied together with ATP, such as TEA\(^{+}\), 4-AP or the specific blocker TRAM-34, inhibited cell migration compared to that of ATP alone. Moreover, the former blocker decreased migration with respect to basal level. Similar to the lack of ATP effect on proliferation and cell survival, TRAM-34 alone had no effect in control experiments with SKOV-3.

SKOV-3 cells that were esiRNA-treated were also tested for motility using a similar protocol; the results are illustrated in Fig. 7D. Groups of esiRNA-transfected cells were tested for migration with 3 µM ATP, 3µM UTP or 300 µM 1-EBIO. The results showed that in P2Y\(_2\)- or K\(_{Ca3.1}\)-esiRNA transfected cells, cell migration was strongly reduced by all drugs tested (compared with CNT group), including the group of P2Y\(_2\)-esiRNA transfected cells tested with 1-EBIO. This suggested that P2Y\(_2\) receptor was required for complete channel activation, a notion that was in agreement with our electrophysiological results.

**K\(_{Ca3.1}\) and P2Y\(_2\) receptor expression in biopsies of human ovarian tumors.** It was also of importance to explore whether or not the main protein elements involved in the generation of the electrical and migration responses were expressed in tumor samples from human ovarian tumors. Figure 8 illustrates that K\(_{Ca3.1}\) and P2Y\(_2\) were expressed in biopsies of papillary serous carcinoma tumors (Patient 1, IC16-532-6) with a high degree of hypertrophy and hyperplasia. It is evident that human tissue expressed abundant K\(_{Ca3.1}\) channel protein with preferential localization in neoplastic cells; nevertheless, some other structures were labeled as well, mainly stromal cells without apparent neoplastic phenotype. The P2Y\(_2\) receptor signal was also localized primarily in areas where tumor cells presented K\(_{Ca3.1}\) protein expression, and several regions showed clear co-localization. Similar results were obtained in biopsies from 5 more patients (Patients numbers IC16-4831-1, IC11-738, IC11-7619-3, IC16-1288, and IC16-1050-9; see Supplementary Figure S3).

**Discussion**

In this study we provide evidence that activation of specific receptors for ATP or histamine elicited an electrical response in SKOV-3 cells, a well-established cell model for human ovarian adenocarcinoma, with epithelial-like
morphology. The electrical response was generated, most probably, as a consequence of the [Ca^{2+}]i increase generated by its release from internal stores, through the activation of specific receptors coupled to G proteins. This idea is supported first, because a [Ca^{2+}]i increase was readily observed when the cells were stimulated by ATP or histamine at μM concentrations, as reported in previous studies, and also because the main electrical response corresponded to the generation of a Ca^{2+}-dependent ionic current. The SKOV-3 response elicited by ATP and histamine had multiple phases; however, an outward current component was the most consistent and prominent. This response was mimicked by applying several purinergic agonists that, together, indicated participation of P2Y receptors sensitive to UTP. Nevertheless, comparatively small and fast inward responses elicited by ATP, but not by UTP (or ADP), seemed to indicate involvement of P2X channels in this particular response. The main UTP-sensitive P2Y receptors are the P2Y_{1}, P2Y_{4} and P2Y_{6} subtypes, and expression analysis by PCR and immunocytochemistry showed that P2Y_{1} and P2Y_{4} were the main receptors expressed in SKOV-3 cells. However, given that the human P2Y_{4} receptor is not activated by ATP, the potency sequence for the distinct agonists...
supported a main role for P2Y₂ receptor involvement. For example, the P2Y₂ receptors expressed in humans are also highly sensitive to Ap₄A, but in SKOV-3 cells this agonist was much less effective than ATP or UTP; moreover, pharmacological data excluded involvement of P2Y₂ since UDP was a weak agonist of the response. Thus, nearly equivalent activation by ATP, UTP, and UTPS, very low sensitivity to UTP, together with middle potency for Ap₄A or ADP clearly indicated a main contribution of the P2Y₂ subtype in the electrical responses elicited by purinergic agonists in SKOV-3 cells. This result also agrees with the EC₅₀ of 400 nM for ATP found here for the outward response generated, since the range reported for the half-maximal effective concentration for P2Y₂ ranged in different cell systems from 100 to 500 nM. The P2Y₂ antagonist, AC-R118925, strongly inhibited the response generated by ATP or UTP, while other antagonistic drugs with high specificity for P2Y₁ or the P2Y₁I subtypes had no effect on SKOV-3 response. It is also important to emphasize the lack of effect by transmitters such as adenosine, acetylcholine or dopamine, suggesting the specificity of the SKOV-3 responses to ATP and histamine. This result is compatible with studies demonstrating that SKOV-3 cells do not present either expression of muscarinic receptors or a Ca²⁺ increase elicited by carbacholine, a muscarinic agonist.

The outward-directed current response was carried mainly by K⁺ ions, as demonstrated by monitoring its reversal potential, which was close to the potential estimated for K⁺ ions in the recording conditions of −96.5 mV, as well as by changing the extracellular K⁺ concentration, which shifted the reversal potential of the response as predicted by the Nernst equation. Moreover, outward current responses elicited by ATP were potently blocked by TEA⁻ or 4-AP, two unpecific K⁺ channel blockers. Treatment of cells with more specific drugs indicated that the main pathway involved did not correspond to activation of two-pore K⁺ channels (TASK-3, TREK-1 and TREK-2), or to Ca²⁺ dependent K⁺ channels sensitive to apamin, some of which are proposed to be related to the cancer process in SKOV-3 cells. However, TRAM-34, a specific drug for Ca²⁺-dependent K⁺ channels of intermediate-conductance, and apamin, a specific blocker of the KCa3.1 subtype, showed that this subtype was activated by SKOV-3 response. Moreover, 1-EBIO, a specific positive modulator for this subtype of channels, showed an effect that was, as expected, dependent on the intracellular Ca²⁺ concentration. Thus, the mechanism that generates the ATP response in SKOV-3 cells more likely involves the activation of P2Y₂ receptors, which produces a [Ca²⁺]i increase and the subsequent opening of Ca²⁺-dependent K⁺ channels sensitive to TRAM-34 and 1-EBIO; these K⁺ channels are of the KCa3.1 subtype expressed in SKOV-3 cells, as confirmed by Western blot analysis and immunofluorescence. Also, apparently KCa3.1 channels were primed by P2Y₂ activation, facilitating their opening. This regulatory mechanism was not studied further here; however, it has been shown that KCa3.1 is post-translationally modulated by phosphorylation of a histidine residue in the C-terminal through nucleoside diphosphate kinase B. A similar mechanism might be responsible for the effect observed during ATP-elicited response in SKOV-3 cells.

All functional and pharmacological evidence was also supported by results of specific downregulation of P2Y₂ or KCa3.1 protein expression using the esiRNA-transfection method. Silencing P2Y₂ or KCa3.1 gene produced a strong downregulation of the respective protein expression, which had a strong impact on generation of electrical response elicited by ATP or UTP that was eliminated. Moreover, a significant reduction in [Ca²⁺]i increase elicited by these agonists was observed using fluorometric analysis. In average, reduction in [Ca²⁺]i increase in cells transfected with P2Y₂-esiRNA was not as robust as that observed for the electrical response, indicating that [Ca²⁺]i increase was probably insufficient for KCa3.1 channel activation, and also probably to deficiencies in the P2Y₂ receptor mechanism that primed the channels. Another observation was that KCa3.1 esiRNA-transfected cells also showed a reduction in [Ca²⁺]i response when ATP or UTP was applied. This might indicate a role of K⁺ channels in [Ca²⁺]i increase, probably through membrane potential regulation that would affect voltage-dependent mechanisms and/or reduce Ca²⁺ influx, among several other possibilities. Similarly, it has been reported that downregulation of nucleoside diphosphate kinase B expression reduces KCa3.1 channel activity in CD4 T cells and decreases Ca²⁺ influx.

Furthermore, Erev obtained during the development of the inward current component seems to indicate the flux of Cl⁻ ions. However, in preliminary results a specific blocker for Ca²⁺-dependent Cl⁻ channels of the TMEM16-A subtype did not inhibit this component; hence, further studies are necessary to define its nature and molecular identity. Finally, a similar current response was observed in the ovarian carcinoma cell line CaOV-3.

A relationship between KCa3.1 channel activation and the process of cell migration has been documented in both normal and pathological conditions. Therefore, we have tested whether or not opening KCa3.1 channels with ATP was an effective way to increase SKOV-3 migration at the low ATP concentrations that activated the electrical response. The results showed that 3 μM ATP application promoted SKOV-3 cell migration and that this was also blocked by TRAM-34 and mimicked by 1-EBIO. A strong inhibition of cell migration was also achieved by downregulation of either P2Y₂ or KCa3.1 protein, an effect that was observed on motility promoted by either ATP, UTP or 1-EBIO. This strongly suggests that an increase of extracellular ATP in the low μ-molar range would have an important consequence in the tumor microenvironment; an effect that would be influenced by a concomitant increase in histamine, which might act directly or indirectly on specific receptors (e.g., by promoting the release of ATP as shown in other cell systems).

Together, the results presented here support the idea that an increase in ATP concentration within the tumor microenvironment might alter the function of channels such as KCa3.1. This would promote cell motility, an effect possibly potentiated by several factors including an increase in the expression of the molecules involved, specifically P2Y₂ receptors and KCa3.1 channels in neoplastic cells. In fact, in distinct cancer cell types it has been shown that cell motility in general is highly dependent on [Ca²⁺]i, acting through a complex machinery of molecules which are, in most cases, Ca²⁺-dependent. Among the molecules involved, those that allow the flux of ions through the cell membrane are essential for the process. Both Ca²⁺-dependent K⁺ channel and Cl⁻ channel activation are required for cell motility, allowing the needed movement of water across the membrane and the cell volume changes, which are membrane mechanisms that are also active during the process of metastasis. There is evidence indicating that this might be the case in some cancer cell types specifically regarding KCa3.1 channels;
for example, bradykinin activation of KCa3.1 channels in human glioma cells promotes their migration in both in vitro and in vivo models31,39. In addition, elevated levels of KCa3.1 expression in breast cancer cells40 and cell renal carcinoma40 correlate with tumor grade and metastatic status. Here, we also show that molecules involved in the SKOV-3 electrical response were robustly expressed in biopsies from human ovarian tumors. A strong expression of both P2Y2 receptors and KCa3.1 channels was observed in human ovarian tumors, and they specifically co-localized in neoplastic cells. Thus, it is proposed that opening of KCa3.1 channels by ATP (and histamine) in human ovarian cancer cells might be one of the mechanisms deregulated during the cancer process, possibly explaining the effects that this transmitter has during tumorigenesis.

It is well known that KCa3.1 channels play a main role in the migration of microglial cells, as part of the normal immune response in the nervous system41, as well as in human dendritic cells42 in activated human T cells43. In this context, there are physiological conditions in which ovarian cells might require the capacity to migrate; for example, during ovulation the ovarian superficial epithelium suffers a rupture that allows oocyte release, which occurs through a mechanism similar to an acute inflammatory reaction44. After the gamete is released the ovarian surface wound is repaired by the epithelium. The latter process requires cell migration, as indicated by the profile of genes expressed during ovulation, that shows a strong correlation with important epithelial functions, such as the inflammation reaction, angiogenesis, extracellular matrix remodeling and cell-to-cell contact45. Both ATP and histamine signaling have been proposed to be involved in ovulation46; in this manner, transmitter-activated membrane ionic currents in the ovarian superficial epithelium might participate during this specific physiological condition, a hypothesis that requires further studies. Nevertheless, an important role for KCa3.1 in general epithelial secretory activity is expected, as suggested by its broad expression in most of the epithelial cells analyzed47.

In summary, in this study we show that purinergic and histaminergic stimulation generated electrical responses in SKOV-3 cells through the opening of membrane ion channels. This has two important implications: first, two main transmitters that are commonly found in increased concentrations in the tumoral microenvironment exerted direct actions on membrane conductivity pathways; and second, activation of one of these pathways, the KCa3.1 channel subtype, was directly involved in SKOV-3 cell motility, an important phenomenon in cancer. Since the P2Y2 receptor and the KCa3.1 channel are co-expressed in neoplastic cells from human ovary, we propose that they may be useful tumor markers as well as targets for therapy to halt ovarian cancer progression.

Methods

Cell cultures. The human ovarian cancer cell line SKOV-3 was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured at 37°C in a humidified atmosphere containing 95% air: 5% CO2 in RPMI1640 growth medium with L-glutamine (Mediatech, Manassas, VA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco, Waltham, MA, USA) and 1% antibiotic-antimycotic mix (streptomycin, penicillin and amphotericin B; Life Technologies, USA). SKOV-3 cells were plated onto 12-mm-diameter coverslips in 12-well culture dishes and after 48 h in culture were used for electrical recording or other experimental protocols such as migration assays or specific protein detection by Western blot or immunolabeling. In some experiments, human ovarian adenocarcinoma CaOV3 cells obtained from ATCC were cultured in a similar manner for in vitro experiments. As control cells, cortical neurons were cultured from brain cerebral cortex of E18 Sprague-Dawley rat embryos48. Briefly, neurons were dissociated enzymatically and mechanically, seeded on poly-D-lysine-covered coverslips and maintained in neurobasal medium supplemented with 10% FBS. Cultures were processed for immunocytochemistry after 7 days in vitro.

Electrophysiology. Whole-cell recordings were performed at room temperature (23–26°C) using the Axon 200B patch-clamp amplifier (Axon Instruments; Sunnyvale, CA, USA). Currents were regularly recorded at a holding membrane potential of −40 mV, digitized and stored using the A/D converter Digidata 1400 and pClamp 10 software (Axon Instruments) for subsequent analysis. The extracellular bath solution adjusted to pH 7.4 contained the following (in mM): 140 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, and 10 HEPES. Patch-clamp pipettes (3–5 MΩ) were filled with internal solution adjusted to pH 7.4 containing (in mM): 130 KCl, 5 NaCl, 2 EGTA, 1 MgCl2, 10 HEPES, 2 Mg-ATP, and 0.2 Na-GTP. The estimated Ca2+ concentration in this solution was 10 nM. In some experiments, the estimated free Ca2+ concentration was increased to 300 nM by changing the EGTA concentration to 2 mM and adding 1.5 mM CaCl2. External solutions with various K+ concentrations were prepared by equimolar substitution of NaCl by KCl to 10, 30 or 60 mM or the KCl concentration was decreased to 1 mM without compensation. Agonists and other drugs were added to the external solution from stock solutions to reach the desired dilution and applied through superfusion. In most cases, peak currents generated at −40 mV by drug superfusion were used in the analysis. Current-voltage (I/V) relationships were built by changing the membrane potential while the cells were held at −40 mV, and the peak membrane current values at the beginning (20 ms) of each step were plotted as in Fig. 4. In some other cases (Fig. 2B) the membrane potential was held at a desired value while drugs were superfused.

Fluorometry. Intracellular [Ca2+]i was monitored using fluorometric techniques. SKOV-3 cells were grown on coverslips and loaded with Fluor4-AM (5 mM; Molecular Probes, Eugene, OR, USA) in the external solution for 30 min at 37°C. Then, cells were washed with external solution for 10 min to eliminate excess dye and placed in a constant-flow recording chamber that allowed visualization of the cells using an inverted fluorescence microscope (Olympus; Melville, NY, USA). Drugs were applied by superfusion, and responses were recorded with an Evolution QEI camera (Media Cybernetics; Bethesda, MD, USA). Sequences of images were analyzed using the Image-Pro Plus software (Media Cybernetics) and ImageJ software (NIH; Bethesda, MD, USA).

Reverse Transcription Polymerase Chain Reaction. Total RNA from SKOV-3 cells was purified using the guanidine isothiocyanate method. First strand cDNA was synthesized using 2 μg of DNase-treated RNA as
template, 1 µg of oligo(dT), 1.5 µg of random hexamers, and reverse transcriptase. The cDNA was used as template in a polymerase chain reaction to amplify cDNA fragments for β-actin, P2Y₂, P2Y₄, and P2Y₆ transcripts. All the PCR programs started at 96 °C for 2 min and finished at 72 °C for 5 min. The amplification cycles consisted of 1 cycle of 96 °C, 30 s at the specific annealing temperature for each primer set, and 40 s at 72 °C.

The sequences of the oligonucleotides, the annealing temperatures, and the number of PCR cycles used were as follows: P2Y₂, forward GGAGGAACTGGGATAACAGTG, reverse GGGCAGTCTCTGCTGTTGAT, annealing temperature 55 °C, 30 cycles; P2Y₄, forward GGGACTAACCTGCGAGCAG, reverse GATAACATCGAGCCGCTGT, annealing temperature 60 °C, 40 cycles; P2Y₆, forward TTTCGAAGCGTCTGCTGAA, reverse TGGCACATAAAAGGCGT, annealing temperature 55 °C, 30 cycles; and β-actin, forward GGAGAAGACGTT, annealing temperature 55 °C, 25 cycles. The amplified products were gel isolated and subcloned into the pET1.2/blunt vector (Thermo Fisher Scientific, Waltham, MA USA); then, the nucleotide sequences were confirmed by automatic sequencing.

Western blot. Cultured SKOV-3 cells were scraped in Laemmli buffer and boiled for 5 min. For electrophoresis, samples were fractionated in a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (BioRad; Hercules, CA, USA). Membranes were blocked for 1 h at room temperature in 150 mM NaCl, 20 mM Tris, pH 7.4, and 0.1% Tween 20 (TBS-T) containing 5% nonfat dry milk and then incubated overnight at 4 °C with the appropriate mouse monoclonal antibody (1:1000) directed against the Kᵥ₃.1 channel protein (ALM-051, Alomone; Jerusalem, Israel). After washing with TBS-T, membranes were incubated for 1 h at 37 °C with HRP-conjugated goat anti-rabbit antibody (Zymed; Grand Island, NY, USA) to deliver esiRNA into the cells following the method indicated by the manufacturer. After 16 h of incubation with drugs, cells attached on the lower face of the inserts were fixed with 4% paraformaldehyde in PBS for 10 min and stained with 10 µg/ml propidium iodide. The samples were visualized under a microscope, pictures were taken and images were analyzed using ImageJ software (NIH) for quantification.

Immunocytochemistry. For P2Y₂, P2Y₄ or Kᵥ₃.1 channel immunostaining, cells were treated with the corresponding antibody (anti-P2Y₂ (1/100) APRO10; anti-P2Y₄ (1/100) APRO06; or anti-Kᵥ₃.1 (1:1000) ALM051; all from Alomone, Jerusalem, Israel). In all cases the cells were fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. The fixed cultures were permeabilized with 0.1% Tween-20, blocked with 5% goat serum in PBS for 30 min and incubated overnight at 4 °C with the antibodies diluted in PBS containing 5% goat serum and 0.1% Tween-20. Then, cells were rinsed and incubated for 2 h at room temperature with 1:100 anti-mouse IgM-G conjugated with Alexa 488 (Molecular Probes). After three washes with PBS, samples were stained with 4′,6-diamidino-2-phenyl-indole dihydrochloride (DAPI 14 mM, from Molecular Probes). Finally, the samples were mounted on VectaShield (Vector Laboratories; Burlingame, CA, USA), and the preparations were visualized under a laser scanning confocal microscope LSM510 (Zeiss; Oberkochen, Germany).

Migration assay. Transwell assays were performed using 12-well plates containing 8-mm polyethylene hanging cell culture inserts (Millipore; Billerica, MA, USA). The cells were seeded at the apical side of the chamber. The basolateral side was filled with medium supplemented with drugs according to the particular experimental conditions. After 16 h of incubation with drugs, cells attached on the lower face of the inserts were fixed with 4% paraformaldehyde in PBS for 10 min and stained with 10 µg/ml propidium iodide. The samples were visualized under a microscope, pictures were taken and images were analyzed using ImageJ software (NIH) for quantification.

Cell proliferation assay. To analyze cell proliferation and viability, mitochondrial activity of the whole culture was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay (Promega; Wisconsin, USA). For this, cells were cultured in 96-well plates in RPMI-1640–10% FBS, and after 24 h they were transferred to serum-free RPMI-1640 for 8 h. After this, an appropriate stimulus was applied, and the cultures were incubated for an additional 16 h. Finally, the MTS assay was performed as described by the manufacturer. Results were quantified as fold increase of absorbance in experimental conditions relative to unstimulated cells.

esiRNA transfection. SKOV-3 cells were plated at 4 × 10⁴ cells per well in 24-well plates and allowed to attach overnight. Endonuclease prepared small interfering RNAs (esiRNAs) were commercially synthesized (Sigma-Aldrich, St. Louis MO, USA) using either 420 bp length of P2Y₂ receptor (EHU156731; P2Y₂ esiRNA) or 472 bp length of Kᵥ₃.1 channel gene (EHU035251; Kᵥ₃.1 esiRNA), targetng human sequences NM_002564 and NM_002250, respectively. Then, for P2Y₂ receptor or Kᵥ₃.1 channel knockdown, cells were transfected with 150 ng per well of P2Y₂ esiRNA or Kᵥ₃.1 esiRNA, respectively, by using Lipofectamine 3000 (Invitrogen, Grand Island NY, USA) to deliver esiRNA into the cells following the method indicated by the manufacturer. As a non-targeting control (referred to as CNT), was transfected in the same condition the esiRNA of enhanced green fluorescent protein (EHUEGFP, Sigma-Aldrich), all responses of transfected SKOV-3 cells with either P2Y₂-esiRNA or Kᵥ₃.1-esiRNA were compared versus those of the CNT group. Twenty-four to 72 h after transfection, esiRNA-treated SKOV-3 cells maintained in culture were recorded electrically, or used for immunocytochemistry or fluorometric assays, as well as for migration quantification using the methods described above.

Immunohistochemistry in human ovarian cancer biopsies. To explore whether human ovarian tumors express P2Y₂ receptor and Kᵥ₃.1 channel proteins, biopsies of patients with ovarian carcinoma were analyzed by immunohistochemistry. The samples were obtained from the Instituto Nacional de Cancerología (INCAN) México, where clinical histories of all patients are archived, in accordance with ethical procedures approved by the Bioethics Committee. The samples used in the present study correspond to 6 patients diagnosed with ovarian carcinoma. The characteristics of the carcinomas analyzed are as follows: Patient 1 (IC16-532-6), 44 years of age diagnosed with low-grade papillary serous carcinoma; Patient 2 (IC16-4831-1), 61 years of age diagnosed with high-grade papillary serous carcinoma; Patient 3 (IC11-7381), 56 years of age with endometrioid G3-type carcinoma; Patient 4 (IC11-7619-3), 70 years of age diagnosed with high-grade serous carcinoma; Patient
Reagents. All the following drugs were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Tocris Bioscience (Bristol, UK): Adenosine 5′-triphosphate (ATP); uridine 5′-triphosphate (UTP); histamine; adenosine 5′-[(thio)-triphosphate (ATP-S); P1-P3(Dadenosine-5′) tetraphosphate (Ap4A); 2-(Methylthio) adenosine 5′-triphosphate (2-MeSATP); 2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-triphosphate tri(triethylammonium) salt (Bz-ATP); 5-Bromo-2′-deoxyuridine (5Br-UDP); adenosine 5′-diphosphate (ADP); 2-(Methylthio) adenosine 5′-diphosphate (2-MeADP); Uridine 5′-diphosphate (UDP); dopamine; adenosine; acetylcholine; 5′-[[5-(2,8-Dimethyl-5′H-dibenzo[a,d]cyclohept-3-yl)-3,4-dihydro-2-oxo-4-thioo-(2H)-pyrimidinyl]methyl]-N′-H2-tetrazol-5-yl-2-furancarboxamide (AR-C118925); 4,4′-(Carbonylbis(mimo-3,1- (4-methyl-phenylene)2,6-disulfonic acid)] tetrasodium salt (NF340); 2′-Deoxy-N′-methyladenosine 3′,5′-bisphosphatetosodium salt (MRS2179); (E,E)-1,7-bis-[4-Hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione (curcumin); R(+)-Arachidonoyl-1′-hydroxy-2′-propylamide (R(+)-methanamidane); tetratetrapentamidonium chloride (TPeNa); L-2-Amino-4-(methylthio)butanoic acid (L-Methionine); tetraethyleneglycol chloride (TEA+); 4-Aminopiridylidine-1H-pyrazole (TRAM-34); 1-Ethyl-1,3-dihydro-2H-benzimidazol-2-one (1-EBIO); Ethylene glycol-bis-(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). Uridine 5′-[(thio)-triphosphate (UTP+S); 2-([5-Ethyl-1,6-dihydro-4-methyl-6-oxo-2-pyrimidinyl]thio)-N′-[4-(4-methoxyphenyl)-2-thiazolyl]acetamide (T16Ainh-A01); and apamin. All the common salt forms were from Sigma-Aldrich or J.T. Baker (Phillipsburg, NY, USA).

Statistical Analysis. All data are expressed as mean ± S.E.M. The means of two groups were compared using a Student’s t-test, or when appropriate, by analysis of variance followed by post-hoc comparisons of individual means using the Bonferroni correction. Statistical analysis was performed using GraphPad Prism software. Differences were considered to be significant at P < 0.05.

References

1. Burnstock, G. & Di Virgilio, F. Purinergic signalling and cancer. Purinergic Signal. 9, 491–510 (2013).
2. Medina, V. A. & Rivera, E. S. Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 161, 755–67 (2010).
3. Spungin, B. & Friedberg, I. Growth inhibition of breast cancer cells induced by exogenous ATP. Br. J. Pharmacol. 157, 502–8 (1993).
4. Lee, S. G. et al. The effect of adenosine 5′-triphosphate on calcium mobilization and cell proliferation in cervical cancer cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 127, 110–4 (2006).
5. Tu, M. T. et al. P2Y2 receptor-mediated proliferation of C6 glioma cells via activation of Ras/Raf/MEK/MAPK pathway. Br. J. Pharmacol. 129, 1481–9 (2000).
6. Fang, W. G., Pernia, F., Bang, Y. J., Myers, C. E. & Trepel, J. B. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J. Clin. Invest. 89, 191–6 (1992).
7. Frede, J. et al. Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. Eur. J. Cancer 49, 2331–44 (2013).
8. Bates, E. Ion channels in development and cancer. Annu. Rev. Cell Dev. Biol. 31, 231–47 (2015).
9. Haren, N. et al. Intermediate conductance Ca2+-activated K+ channels are expressed and functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol. Histopathol. 25, 1247–55 (2010).
10. Stock, C. & Schwab, A. Ion channels and transporters in metastasis. Biochim. Biophys. Acta 1848, 2638–46 (2015).
11. Zhanping, W., Xiaoyu, P., Na, C., Shenglan, W. & Bo, W. Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell. Gynecol. Oncol. 104, 455–60 (2007).
12. Turner, K. L., Hassagne, A., Robert, S. M., McFerran, M. M. & Southeimer, H. A proinvasive role for the Ca2+-activated K+ channel KCa3.1 in malignant glioma. Glia. 62, 971–81 (2014).
13. Auerperg, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255–88 (2001).
14. Huo, W. et al. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J. Cancer. 8, 57–64 (2017).
15. Vázquez-Cuevas, F. G. et al. Differential expression of the P2X5 receptor in ovarian surface epithelium during the oestrous cycle in the mouse. Reprod. Fertil. Dev. 25, 971–84 (2013).
16. Batra, S. & Fadeel, I. Release of intracellular calcium and stimulation of cell growth by ATP and histamine in human ovarian cancer cells (SKOV-3). Cancer Lett. 77, 57–63 (1994).
17. Innamaa, A. et al. Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer. Clin. Transl. Oncol. 15, 910–8 (2013).
18. Innamaa, A. et al. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res. 33, 1401–8 (2013).
19. Hanna, E. A. et al. Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro. Carcinogenesis 20, 1369–73 (1999).
20. Abbracciochi, M. P. et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58, 281–341 (2006).
21. von Kügelgen, I. & Hoffmann, K. Pharmacology and structure of P2Y receptors. Neurropharmacology 104, 50–61 (2016).
22. Kennedy, C., Qi, A. D., Herold, C. L., Harden, T. K. & Nicholos, R. A. ATP: an agonist at the rat P2Y2 receptor, is an antagonist at the human P2Y2 receptor. Mol. Pharmacol. 57, 926–31 (2000).
23. Rafehi, M., Burbiel, J. C., Attah, I. Y., Abdelrahman, A. & Müller, C. E. Synthesis, characterization, and in vitro evaluation of the selective P2Y2 receptor antagonist AR-C118925. Purinergic Signal. 13, 89–103 (2017).
24. Wulf, H. et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca\(^{2+}\)-activated K\(^+\) channel, IKC\(_{\alpha 1}\): a potential immunosuppressant. Proc. Natl. Acad. Sci. USA 97, 8151–6 (2000).
25. Pedersen, K. A. et al. Activation of the human intermediate-conductance Ca\(^{2+}\)-activated K\(^+\) channel by 1-ethyl-2-benzimidazoloinone is strongly Ca\(^{2+}\)-dependent. Biochim. Biophys. Acta 1420, 231–40 (1999).
26. Devor, D. C., Singh, A. K., Fritzel, R. A. & Bridges, R. J. Modulation of Cl\(^-\) secretion by benzimidazolones. I. Direct activation of a Ca\(^{2+}\)-dependent K\(^+\) channel. Am. J. Physiol. 271, L775–84 (1996).
27. Jensen, B. S. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J. Biol. Chem. 288, 27571–83 (2013).
28. Turner, R. W. et al. Neuronal expression of the intermediate conductance calcium-activated potassium channel K\(_{\text{Ca}}\)3.1 in the mammalian central nervous system. Pflügers Arch. Eur. J. Physiol. 467, 311–28 (2015).
29. Schwab, A., Hanley, P., Fabian, A. & Stock, C. Potassium channels keep mobile cells on the go. Physiol. (Bethesda). 23, 212–220 (2008).
30. Ferreira, R. & Schlichter, L. C. Selective activation of K\(_{\text{Ca}}\)3.1 and CRAC channels by P2Y2 receptors promotes Ca\(^{2+}\) signaling, store refilling and migration of rat microglial cells. PloS One 8, e62345 (2013).
31. Ruggieri, P. et al. The inhibition of K\(_{\text{Ca}}\)3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PloS One 7, e47825 (2012).
32. Schwab, A., Reinhardt, J., Schneider, S. W., Gassner, B. & Schuricht, B. K+ channel-dependent migration of fibroblasts and human melanoma cells. Cell. Physiol. Biochem. 9, 126–32 (1999).
33. Janssens, R., Paindavoine, P., Parmentier, M. & Boeynaems, J. M. Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants. Br. J. Pharmacol. 127, 709–16 (1999).
34. Lazarowski, E. R., Watt, W. C., Stutts, M. J., Boucher, R. C. & Harden, T. K. Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br. J. Pharmacol. 116, 1619–27 (1995).
35. Batra, S., Popper, L. D. & Josif, C. S. Characterisation of muscarinic cholinergic receptors in human ovaries, ovarian tumours and tumour cell lines. Eur. J. Cancer 29A, 1302–6 (1993).
36. Srivastava, S. et al. Histidine phosphorylation of the potassium channel K\(_{\text{Ca}}\)3.1 by nucleoside diphosphate Kinase B is required for activation of K\(_{\text{Ca}}\)3.1 and CD4 T cells. Mol. Cell. 24, 665–75 (2006).
37. Pinheiro, A. R. et al. Histamine induces ATP release from human subcutaneous fibroblasts, via pannexin-1 hemichannels, leading to Ca\(^{2+}\) mobilization and cell proliferation. J. Biol. Chem. 288, 27571–83 (2013).
38. Turner, K. L. & Sontheimer, H. Cl\(^-\) and K\(^+\) channels and their role in primary brain tumour biology. Philos Trans R Soc Lond B Biol Sci. 369, 20130095 (2014).
39. D’Alessandro, G. et al. K\(_{\text{Ca}}\)3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis. 4, e773 (2013).
40. Rabjerg, M. et al. High expression of K\(_{\text{Ca}}\)3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival. PloS One 10, e0122992 (2015).
41. Crottès, D. et al. Immature human dendritic cells enhance their migration through K\(_{\text{Ca}}\)3.1 channel activation. Cell Calcium 59, 198–207 (2016).
42. Kuras, Z., Yun, Y.-H., Chimote, A. A., Neumeier, L. & Conforti, L. K\(_{\text{Ca}}\)3.1 and TRPM7 channels at the uropod regulate migration of activated human T cells. PloS One 7, e38599 (2012).
43. Eapen, L. Comprehensive analysis of ovarian gene expression during ovulation using differential display. Methods Mol. Biol. 317, 219–41 (2006).
44. Wissing, M. L. et al. Identification of new ovulation-related genes in humans by comparing the transcriptome of granulosa cells before and after ovulation triggering in the same controlled ovarian stimulation cycle. Hum. Reprod. 29, 997–1010 (2014).
45. Thompson-Vest, N., Shimizu, Y., Hunne, B. & Furness, J. B. The distribution of intermediate-conductance, calcium-activated, potassium IK channels in epithelial cells. J. Anat. 208, 219–29 (2006).
46. Soria, F. N. et al. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J. Clin. Invest. 124, 3645–55 (2014).

Acknowledgements
We are grateful to Dr. Dorothy D. Pless and Jessica González Norris for their editorial assistance. We also thank Mr. Horacio Ramirez Leyva, Ing. Nydia Hernández-Rios, M. en C. Leonor Casanova, M.V.Z. Martín García Servin, and Ing. Ramón Martínez Olivera for their expert technical support. This study was supported by grants from CONACyT-México No. 82340 and No. 252121, and PAPIIT-UNAM-México No. IN205615 to R.O.A. laboratory. M.G.M.-G. is a postdoctoral researcher from DGAPA-UNAM; and L.R.-M., is a doctoral student from Programa de Doctorado en Ciencias Biomédicas at Universidad Nacional Autónoma de México (UNAM) and received fellowship No. 229134 from CONACyT.

Author Contributions
L.R.-M., E. G., and R.O.A. conceived the experimental part of the study. L.R.-M., R.O.A., E. G., A.C.-M., M.G.M.-G., and A.L. performed experiments. D.P.-M. conducted the pathology analysis. L.R.-M., E. G., and R.O.A. wrote the manuscript. All authors analyzed the results and critically commented on the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04292-6

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
